中国麻风皮肤病杂志 ›› 2023, Vol. 39 ›› Issue (2): 102-105.doi: 10.12144/zgmfskin202302102

• 临床研究 • 上一篇    下一篇

巴瑞替尼治疗进展期白癜风疗效分析

李子航,王睿,张昕   

  1. 解放军总医院第一医学中心皮肤科，北京，100853
  • 出版日期:2023-02-15 发布日期:2022-12-27

Efficacy of baricitinib in the treatment of progressive vitiligo

LI Zihang, WANG Rui, ZHANG Xin   

  1. Department of Dermatology, the First Medical Center of PLA General Hospital, Beijing 100853, China
  • Online:2023-02-15 Published:2022-12-27

PDF (PC)

298

摘要： 目的：评价巴瑞替尼治疗白癜风的疗效及安全性。方法：收集2021年4月至2022年3月因系统用糖皮质激素治疗无效或拒绝使用糖皮质激素而接受巴瑞替尼治疗的病例，在第3、6个月评价其疗效。结果：共收集患者8例，经过3、6个月治疗后，显效率分别为35.3%、55.9%，总有效率分别为67.6%、73.5%。治疗6个月的患者，肢端的疗效低于躯干（总有效率χ2=7.369，P＜0.01）和四肢（总有效率χ2=4.554，P＜0.05）的疗效。结论：巴瑞替尼治疗进展期白癜风安全有效，其疗效受治疗时间、皮损部位的影响。

关键词: 白癜风, JAK抑制剂, 巴瑞替尼

Abstract: Objective: To assess the efficacy and safety of baricitinib in the treatment of patient with progressive vitiligo. Methods: Patients with vitiligo received baritinib from April 2021 to March 2022 due to failure of systemic hormone therapy or refusal to use glucocorticoids were collected and evaluated at 3 and 6 months. Results: 8 patients were collected. After 3 and 6 months of treatment, the significant efficiency was 35.3% and 55.9%, and the total effective rate was 67.6% and 73.5%, respectively. After 6 months of treatment, the efficacy of extremities was lower than that of trunk (total effective rate χ2=7.369, P<0.01) and limbs (total effective rate χ2=4.554, P<0.05).  Conclusion: Baricitinib is effective and safe for progressive vitiligo，which is affected by duration of treatment and location of lesions.

Key words: vitiligo, JAK inhibitors, baricitinib